e-learning
resources
Copenhagen 2005
Wednesday 21.09.2005
Pulmonary hypertension: pathophysiology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats
S. A. Hamidi, K. G. Dickman, S. Mathew, S. I. Said (Northport, Stony Brook, United States Of America)
Source:
Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Session:
Pulmonary hypertension: pathophysiology
Session type:
Oral Presentation
Number:
4427
Disease area:
Pulmonary vascular diseases, Respiratory critical care
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. A. Hamidi, K. G. Dickman, S. Mathew, S. I. Said (Northport, Stony Brook, United States Of America). Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats. Eur Respir J 2005; 26: Suppl. 49, 4427
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
The physiology of breathlessness
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Inhalation of vasoactive intestinal peptide in pulmonary hypertension
Source: Eur Respir J 2008; 32: 1289-1294
Year: 2008
Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2006 - Cellular mechanisms of airway disease
Year: 2006
Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets
Source: Eur Respir J 2006; 28: Suppl. 50, 659s
Year: 2006
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2011; 37: 1104-1118
Year: 2011
Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension
Source: Annual Congress 2005 - Scientific year in review
Year: 2005
Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Inhalation of vasoactive intestinal peptide in pulmonary hypertension
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008
In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
High-altitude disease
Source: Respipedia Article
Year: 2017
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats
Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension
Year: 2009
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
The effect of acetazolamide on pulmonary hypertension induced by chronic hypoxia in rats
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Role of anti-proliferative therapy in PAH
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Stress failure plays a major role in the development of high-altitude pulmonary oedema in rats
Source: Eur Respir J 2010; 35: 584-591
Year: 2010
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition
Source: Eur Respir J 2008; 31: 599-610
Year: 2008
Protection of vasoconstriction and lung function impairment by endothelin-receptor blockers and vasoactive intestinal peptide (VIP) in isolated perfused rat lungs
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept